{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:13:12Z","timestamp":1786889592173,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":75,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.prp.2023.154562","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T11:33:12Z","timestamp":1684495992000},"page":"154562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The role of High-mobility group box-1 and Psoriasin in multiple myeloma: Analysis of a population affected by monoclonal gammopathies and review of the literature"],"prefix":"10.1016","volume":"247","author":[{"given":"Marco","family":"Casciaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Vincelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mirabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pioggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154562_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","article-title":"New drugs in multiple myeloma","volume":"70","author":"Kunacheewa","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.prp.2023.154562_bib2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"14","key":"10.1016\/j.prp.2023.154562_bib3","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3390\/cancers14112597","article-title":"Epigenetic crosstalk between malignant plasma cells and the tumour microenvironment in multiple myeloma","volume":"24","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.prp.2023.154562_bib4","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2023.154562_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/iid3.370","article-title":"The performance of the alarmin HMGB-1 in pediatric diseases: from lab to clinic","volume":"9","author":"Li","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.prp.2023.154562_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/JLB.3MIR1218-497R","article-title":"Location is the key to function: HMGB-1 in sepsis and trauma-induced inflammation","volume":"106","author":"Deng","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154562_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1189\/jlb.0806540","article-title":"Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB-1","volume":"81","author":"Tang","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154562_bib8","first-page":"61","article-title":"HMGB-1 participates in LPS-induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE\/NF-\u03baB signaling pathways","volume":"45","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.prp.2023.154562_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","article-title":"HMGB-1 signals through toll-like receptor (TLR) 4 and TLR2","volume":"26","author":"Yu","year":"2006","journal-title":"Shock"},{"key":"10.1016\/j.prp.2023.154562_bib10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/labinvest.2009.47","article-title":"Non-histone nuclear factor HMGB-1 is phosphorylated and secreted in colon cancers","volume":"89","author":"Kang","year":"2009","journal-title":"Lab Invest"},{"key":"10.1016\/j.prp.2023.154562_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0968-0004(01)01801-1","article-title":"HMGB 1 and 2 and related \u2018architectural\u2019 DNA binding proteins","volume":"26","author":"Thomas","year":"2001","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.prp.2023.154562_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High mobility group box 1 protein (HMGB-1). Nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2023.154562_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/07357900801954210","article-title":"Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin","volume":"26","author":"Sharma","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1016\/j.prp.2023.154562_bib14","first-page":"425","article-title":"Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB-1) expression leads to inhibition of prostate cancer cell survival and apoptosis","volume":"34","author":"Gnanasekar","year":"2009","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.12659\/MSM.890531","article-title":"The role of High Mobility Group Box 1 (HMGB-1) in colorectal cancer","volume":"20","author":"Suren","year":"2014","journal-title":"Med Sci. Monit."},{"key":"10.1016\/j.prp.2023.154562_bib16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1096\/fj.02-0621fje","article-title":"HMGB-1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma","volume":"17","author":"Brezniceanu","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.prp.2023.154562_bib17","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3892\/ol.2012.1091","article-title":"Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma","volume":"5","author":"Wang","year":"2013","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.prp.2023.154562_bib18","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cancers12092435","article-title":"The HMGB-1-2 ovarian cancer interactome. The role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response","volume":"27","author":"C\u00e1mara-Qu\u00edlez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2023.154562_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-020-00920-3","article-title":"High mobility group box 1 (HMGB-1): a pivotal regulator of hematopoietic malignancies","volume":"13","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12484041","article-title":"Molecular cloning, occurrence, and expression of a novel partially secreted protein \"psoriasin\" that is highly up-regulated in psoriatic skin","volume":"97","author":"Madsen","year":"1991","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.prp.2023.154562_bib21","first-page":"81","article-title":"Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes","volume":"25","author":"Jiang","year":"2004","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.urolonc.2012.05.006","article-title":"Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells","volume":"31","author":"Ye","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-006-0164-y","article-title":"Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours","volume":"133","author":"Moubayed","year":"2007","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011939","article-title":"Nuclear S100A7 is associated with poor prognosis in head and neck cancer","volume":"5","author":"Tripathi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2023.154562_bib25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0022-5347(01)66118-4","article-title":"Bladder squamous cell carcinomas express psoriasin and externalize it to the urine","volume":"155","author":"Celis","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2023.154562_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/1471-2407-12-588","article-title":"The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions","volume":"12","author":"Hu","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.prp.2023.154562_bib27","first-page":"493","article-title":"The Value of Serum HMGB-1 and sRAGE in the diagnosis, efficacy monitoring and prognosis of newly diagnosed multiple myeloma","volume":"30","author":"Wang","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.prp.2023.154562_bib28","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cells9071664","article-title":"High mobility group box 1 in human","volume":"9","author":"Rapoport","year":"2020","journal-title":"Cancer Cells"},{"key":"10.1016\/j.prp.2023.154562_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","article-title":"HMGB-1 in inflammation and cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib30","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"3rd; Lotze, M.T.; Tang, D. HMGB-1 in cancer: Good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin. Cancer Res. . J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2023.154562_bib31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2795.x","article-title":"Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies","volume":"77","author":"Quartarone","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.prp.2023.154562_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hon.865","article-title":"Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases","volume":"26","author":"Alonci","year":"2008","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antiox8030055","article-title":"Evaluation of the AGE\/sRAGE axis in patients with multiple myeloma","volume":"8","author":"Allegra","year":"2019","journal-title":"Antioxidants"},{"issue":"16","key":"10.1016\/j.prp.2023.154562_bib34","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.3390\/ijms22169039","article-title":"Involvement of alarmins in the pathogenesis and progression of multiple myeloma","volume":"22","author":"Murdaca","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154562_bib35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/344830a0","article-title":"Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins","volume":"344","author":"Jantzen","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.prp.2023.154562_bib36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.biocel.2007.11.014","article-title":"HMGB-1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail","volume":"40","author":"Topalova","year":"2008","journal-title":"Int J. Biochem Cell Biol."},{"key":"10.1016\/j.prp.2023.154562_bib37","first-page":"1259","article-title":"Not just nuclear proteins: \u2018novel\u2019 autophagy cancer treatment targets - p53 and HMGB-1","volume":"9","author":"Livesey","year":"2008","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.prp.2023.154562_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/gut.2004.062729","article-title":"Increased expression of high mobility group box 1 (HMGB-1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas","volume":"55","author":"V\u00f6lp","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.prp.2023.154562_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2023.154562_bib40","first-page":"413","article-title":"High mobility group box-1 and its clinical value in breast cancer","volume":"8","author":"Sun","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.prp.2023.154562_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JP9.0000000000000002","article-title":"The dual role of HMGB-1 in pancreatic cancer","volume":"1","author":"Kang","year":"2018","journal-title":"J. Pancreatol."},{"key":"10.1016\/j.prp.2023.154562_bib42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/cr.2017.51","article-title":"Intracellular HMGB-1 as a novel tumor suppressor of pancreatic cancer","volume":"27","author":"Kang","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.prp.2023.154562_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1158\/1535-7163.MCT-08-0695","article-title":"Chromatin-associated proteins HMGB-1\/2 and PDIA3 trigger cellular response to chemotherapy induced DNA damage","volume":"8","author":"Krynetskaia","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2023.154562_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1189\/jlb.0306169","article-title":"Cytolytic cells induce HMGB-1 release from melanoma cell lines","volume":"81","author":"Ito","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154562_bib45","doi-asserted-by":"crossref","first-page":"107500","DOI":"10.18632\/oncotarget.22494","article-title":"MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB-1-mediated autophagy","volume":"8","author":"Xiong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154562_bib46","first-page":"5611","article-title":"MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma","volume":"14","author":"Li","year":"2017","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.prp.2023.154562_bib47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.biopha.2017.09.045","article-title":"Long noncoding RNA PCAT-1 promotes invasion and metastasis via the miR129-5p-HMGB-1 signaling pathway in hepatocellular carcinoma","volume":"95","author":"Zhang","year":"2017","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.prp.2023.154562_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13046-018-0883-3","article-title":"HMGB-1 knock-down increases MM cell vulnerability by regulating autophagy and DNA damage repair","volume":"37","author":"Guo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154562_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3892\/etm.2021.10137","article-title":"HMGB-1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-\u03baB pathway","volume":"22","author":"Ning","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.prp.2023.154562_bib50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cancers13040766","article-title":"Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"13","author":"Li","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154562_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/ijms22010367","article-title":"Role of HMGB-1 in chemotherapy-induced peripheral neuropathy","volume":"22","author":"Sekiguchi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154562_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tox.2016.07.016","article-title":"Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats","volume":"365","author":"Nishida","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.prp.2023.154562_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2018.08.040","article-title":"Paclitaxel-induced HMGB-1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk","volume":"141","author":"Sekiguchi","year":"2018","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.prp.2023.154562_bib54","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/cells10102550","article-title":"Caspase-dependent HMGB-1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"10","author":"Tsubota","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prp.2023.154562_bib55","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbrc.2007.06.065","article-title":"Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer","volume":"360","author":"Maeda","year":"2007","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.prp.2023.154562_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nbd.2011.12.056","article-title":"Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB-1 phosphorylation and secretion","volume":"46","author":"Kim","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.prp.2023.154562_bib57","first-page":"425","article-title":"Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB-1) expression leads to inhibition of prostate cancer cell survival and apoptosis","volume":"34","author":"Gnanasekar","year":"2009","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.prp.2023.154562_bib58","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB-1 in cancer: good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154562_bib59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00428-006-0359-2","article-title":"The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma","volume":"450","author":"Sasahira","year":"2007","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.prp.2023.154562_bib60","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00726-010-0666-4","article-title":"Novel S100A7 (psoriasin)\/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function","volume":"41","author":"Wolf","year":"2011","journal-title":"Amino Acids"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:00:07Z","timestamp":1759734007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":60,"alternative-id":["S0344033823002625"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154562","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of High-mobility group box-1 and Psoriasin in multiple myeloma: Analysis of a population affected by monoclonal gammopathies and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154562"}}